<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04273607</url>
  </required_header>
  <id_info>
    <org_study_id>19-5692.0</org_study_id>
    <nct_id>NCT04273607</nct_id>
  </id_info>
  <brief_title>Anticoagulation-free VV ECMO for Acute Respiratory Failure</brief_title>
  <acronym>A-FREE ECMO</acronym>
  <official_title>Anticoagulation-free VV ECMO for Acute Respiratory Failure: A Pilot Safety and Feasibility Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damian Ratano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Physicians' Services Incorporated (PSI) Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently international experts recommend therapeutic anticoagulation for veno-venous
      extracorporeal membrane oxygenation (VV-ECMO). Reports and case series suggest that the
      absence of therapeutic anticoagulation is safe for VV-ECMO. No randomized control trials have
      assessed this. The aim of this pilot study is to assess safety and feasibility of an
      &quot;anticoagulation-free strategy&quot; for veno-venous ECMO (VV-ECMO) in Acute respiratory distress
      syndrome (ARDS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although anticoagulation targets and monitoring strategies vary around the world, the current
      practice is still to anticoagulate patients on ECMO, mostly with UFH. However, the use of
      heparin coated circuits has changed their thrombogenicity. Preliminary data suggest that a
      low-dose unfractionated heparin (UFH) strategy is non-inferior to a therapeutic dose UFH.
      Indeed, in daily practice, when a patient on ECMO has severe bleeding complications, UFH is
      often stopped until the hemorrhagic issue is under control, sometimes for days. This has led
      some to hypothesize that anticoagulation might not be necessary for VV-ECMO, and a few case
      series report little to no increase in adverse events as a result. There are currently no
      randomized controlled trials comparing anticoagulation to no anticoagulation for patients
      supported with ECMO. Anticoagulation is, for physiological reasons, less necessary during
      VV-ECMO than VA-ECMO and this is the reason why our pilot study will focus on VV-ECMO only.
      Whereas the whole ECMO device is identical for both configurations, the risk of systemic
      embolization (e.g., stroke) and its severe complications is much higher in VA-ECMO where
      blood is reinjected directly into the systemic arterial system. Moreover, in the presence of
      severely decreased left ventricular function requiring VA-ECMO, the risk of left ventricular
      thrombus is very high and requires anticoagulation. During VV-ECMO, the risk of systemic
      embolization is low because the whole circuit is on the right side of the heart and
      relatively preserved biventricular function is needed to perform VV-ECMO

      The hypothesis is that VV-ECMO is safe and feasible without therapeutic anticoagulation for
      adults with ARDS.

      The objectives of this study is to assess, through a pilot study, the safety and feasibility
      of an &quot;anticoagulation free strategy&quot; for veno-venous ECMO (VV-ECMO) in acute respiratory
      failure
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 6, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ECMO associated thrombotic complications</measure>
    <time_frame>through ECMO completion, an average of 14 days</time_frame>
    <description>Composite outcome of:
ECMO membrane oxygenator function assessed by trans-membrane pressure drop (&gt; 10mmHg/l/min) and a membrane PaO2/FiO2 ratio (&lt; 200mmHg)
Need to change ECMO circuit due to clotting or dysfunction
Platelets drop &gt;50% in 24 hours and &lt;50 /mm3
Development of a clinically significant thromboembolic event
Clinical deep vein thrombosis, clinically suspected and confirmed by ultrasound
Acute ischemic stroke, clinically suspected and confirmed by head-CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic complications</measure>
    <time_frame>through ECMO completion, an average of 14 days</time_frame>
    <description>Hemorrhagic complications assessed and adapted as per Bleeding Academic Research Consortium (BARC)
Type 0: No bleeding
Type 1: Bleeding requiring transfusion of packed red blood cells (PRBC) or reduction of UFH
Type 2: Bleeding requiring transfusion of PRBC and reduction of UFH
Type 3: Life-threatening bleeding requiring, transfusion of PRBC, surgical intervention or discontinuation of ECMO
Type 4: Any fatal bleeding</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Increase in d-dimer levels</measure>
    <time_frame>through ECMO completion, an average of 14 days</time_frame>
    <description>D-dimers level (&gt;5000ng/ml or &gt;50% increase in 24 h)
Need for transfusion of blood and blood-derived products related or not to a bleeding event
Coagulation parameters during the ECMO period
Amount of clot and fibrin visualized in the pre- and post-membrane side of the oxygenator daily (visual assessment) and after ECMO removal (assessed by a photographic quantification method).</description>
  </other_outcome>
  <other_outcome>
    <measure>Transfusion of blood and blood-derived products related or not to a bleeding event</measure>
    <time_frame>through ECMO completion, an average of 14 days</time_frame>
    <description>Amount of blood products transfused to patients in each groups during the course of ECMO</description>
  </other_outcome>
  <other_outcome>
    <measure>Coagulation parameters on ECMO</measure>
    <time_frame>through ECMO completion, an average of 14 days</time_frame>
    <description>Evaluation of fibrinogen (g/l), activated partial thromboplastin time (aPTT, seconds), prothrombin time (PT, seconds), thromboelastogram (if available), activated clotting time (ACT, seconds; if available)</description>
  </other_outcome>
  <other_outcome>
    <measure>Amount of clot and fibrin visualized in the pre- and post-membrane side</measure>
    <time_frame>through ECMO completion, an average of 14 days</time_frame>
    <description>Pragmatic quantification of clot visualized on both sides of the oxygenator by direct evaluation and by a photographic quantification method</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Extracorporeal Membrane Oxygenation Complication</condition>
  <arm_group>
    <arm_group_label>No anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will not receive unfractionated heparin during the course of ECMO. They will receive standard venous thromboembolism prophylaxis with subcutaneous enoxaparin or unfractionated heparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anticoagulation, ECMO standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in this arm will receive the standard of care anticoagulation with unfractionated heparin during the course of ECMO.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous Heparin</intervention_name>
    <description>The intervention group will receive prophylactic heparin instead of standard of care therapeutic intravenous heparin</description>
    <arm_group_label>No anticoagulation</arm_group_label>
    <other_name>Enoxaparin or unfractionated heparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient with ARDS on VV-ECMO

        Exclusion Criteria:

          -  Contraindication to anticoagulation with UFH (known heparin-induced thrombocytopenia,
             active hemorrhage, any surgery precluding the use of anticoagulation),

          -  Indication for therapeutic anticoagulation (pulmonary embolism or deep vein
             thrombosis, chronic anticoagulation therapy before ECMO insertion)

          -  Low-flow (&lt;2 liters/min) VV-ECMO (ECCO2R)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damian Ratano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eddy Fan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Damian Ratano, MD</last_name>
    <phone>+1 416-340-3601</phone>
    <email>damian.ratano@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eddy Fan, MD, PhD</last_name>
    <phone>+1 416-340-3601</phone>
    <email>eddy.fan@uhn.ca</email>
  </overall_contact_backup>
  <link>
    <url>https://www.getinge.com/siteassets/products-a-z/quadrox-i-adult--small-adult/quadroxi_smalladult_adult_mcp_br_10075_en_1_screen.pdf</url>
    <description>Quadrox-i technical specificities</description>
  </link>
  <reference>
    <citation>Krueger K, Schmutz A, Zieger B, Kalbhenn J. Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients. Artif Organs. 2017 Feb;41(2):186-192. doi: 10.1111/aor.12737. Epub 2016 Jun 3.</citation>
    <PMID>27256966</PMID>
  </reference>
  <reference>
    <citation>Whittlesey GC, Drucker DE, Salley SO, Smith HG, Kundu SK, Palder SB, Klein MD. ECMO without heparin: laboratory and clinical experience. J Pediatr Surg. 1991 Mar;26(3):320-4; discussion 324-5.</citation>
    <PMID>2030479</PMID>
  </reference>
  <reference>
    <citation>Wen PH, Chan WH, Chen YC, Chen YL, Chan CP, Lin PY. Non-heparinized ECMO serves a rescue method in a multitrauma patient combining pulmonary contusion and nonoperative internal bleeding: a case report and literature review. World J Emerg Surg. 2015 Mar 12;10:15. doi: 10.1186/s13017-015-0006-9. eCollection 2015.</citation>
    <PMID>25774211</PMID>
  </reference>
  <reference>
    <citation>Dornia C, Philipp A, Bauer S, Stroszczynski C, Schreyer AG, M端ller T, Koehl GE, Lehle K. D-dimers Are a Predictor of Clot Volume Inside Membrane Oxygenators During Extracorporeal Membrane Oxygenation. Artif Organs. 2015 Sep;39(9):782-7. doi: 10.1111/aor.12460. Epub 2015 Apr 7.</citation>
    <PMID>25845704</PMID>
  </reference>
  <reference>
    <citation>Lubnow M, Philipp A, Dornia C, Schroll S, Bein T, Creutzenberg M, Diez C, Schmid C, Pfeifer M, Riegger G, M端ller T, Lehle K. D-dimers as an early marker for oxygenator exchange in extracorporeal membrane oxygenation. J Crit Care. 2014 Jun;29(3):473.e1-5. doi: 10.1016/j.jcrc.2013.12.008. Epub 2013 Dec 30.</citation>
    <PMID>24508200</PMID>
  </reference>
  <reference>
    <citation>Lehle K, Philipp A, Gleich O, Holzamer A, M端ller T, Bein T, Schmid C. Efficiency in extracorporeal membrane oxygenation-cellular deposits on polymethylpentene membranes increase resistance to blood flow and reduce gas exchange capacity. ASAIO J. 2008 Nov-Dec;54(6):612-7. doi: 10.1097/MAT.0b013e318186a807.</citation>
    <PMID>19033775</PMID>
  </reference>
  <reference>
    <citation>Sidebotham D, Allen SJ, McGeorge A, Ibbott N, Willcox T. Venovenous extracorporeal membrane oxygenation in adults: practical aspects of circuits, cannulae, and procedures. J Cardiothorac Vasc Anesth. 2012 Oct;26(5):893-909. doi: 10.1053/j.jvca.2012.02.001. Epub 2012 Apr 13. Review.</citation>
    <PMID>22503344</PMID>
  </reference>
  <reference>
    <citation>Lubnow M, Philipp A, Foltan M, Bull Enger T, Lunz D, Bein T, Haneya A, Schmid C, Riegger G, M端ller T, Lehle K. Technical complications during veno-venous extracorporeal membrane oxygenation and their relevance predicting a system-exchange--retrospective analysis of 265 cases. PLoS One. 2014 Dec 2;9(12):e112316. doi: 10.1371/journal.pone.0112316. eCollection 2014.</citation>
    <PMID>25464516</PMID>
  </reference>
  <reference>
    <citation>Panigada M, E Iapichino G, Brioni M, Panarello G, Protti A, Grasselli G, Occhipinti G, Novembrino C, Consonni D, Arcadipane A, Gattinoni L, Pesenti A. Thromboelastography-based anticoagulation management during extracorporeal membrane oxygenation: a safety and feasibility pilot study. Ann Intensive Care. 2018 Jan 16;8(1):7. doi: 10.1186/s13613-017-0352-8.</citation>
    <PMID>29340875</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 11, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Damian Ratano</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Extracorporeal membrane oxygenation</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>Hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

